Search Clinical Trials in the European Union

Duration
Visits
Phase
Injection
Benefits
Drugs
Locations
Clinical Specialty
501-520 of 2,120 trials

Epithelial Ovarian Cancer: Sentinel Node Detection Study

We are testing two tracers to see if they improve the detection of sentinel lymph nodes in patients with early-stage epithelial ovarian cancer. This may help in better understanding the cancer's spread and improving surgical outcomes.

Ovarian Epithelial Cancer>2 yearsEfficacy phase (II)Standard MedicinesGynecology and ObstetricsOncology

Hypophosphatasia: ALXN1850 Treatment Study

We are studying a new treatment called ALXN1850 for adolescents and adults with hypophosphatasia who haven't been treated before. The goal is to see if it improves their daily functioning and quality of life compared to a placebo.

Hypophosphatasia>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesPartially RemoteEndocrinologyHematology

Hypophosphatasia in Children: ALXN1850 Study

We are studying a new treatment, ALXN1850, for children with hypophosphatasia who haven't been treated before. The goal is to see if it improves bone health and quality of life compared to a placebo.

Hypophosphatasia3-6 monthsConfirmation phase (III)16-20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteOrthopedics and TraumatologyPediatrics

Ulcerative Colitis: Lutikizumab Treatment Study

We are assessing the safety and effectiveness of lutikizumab in adults with active ulcerative colitis. This study compares it to an existing treatment to see if it offers better results.

Ulcerative Colitis1-2 yearsEfficacy phase (II)>20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteGastroenterologyInternal Medicine

Postoperative Pain Relief: Ibuprofen and Tramadol Combination

We are studying a new combination treatment for patients with severe pain after surgery to see if it provides better pain relief than tramadol alone and a placebo. This trial aims to assess both effectiveness and safety.

Acute Pain6-12 monthsConfirmation phase (III)≤5 visitsInvestigational MedicinesInternal MedicineOrthopedics and TraumatologyOtolaryngology

Axial Spondyloarthritis: Imaging with Technetium-labeled Certolizumab Pegol

We are studying whether a new imaging method can improve treatment decisions for people with axial spondyloarthritis. This may help doctors better assess disease activity and predict treatment responses.

Axial Spondyloarthritis>2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesInternal MedicineRheumatology

HER2-Positive Biliary Tract Cancer: GemCis with Trastuzumab and Pembrolizumab

We are studying a combination of treatments for people with HER2-positive biliary tract cancer to see if it improves response rates and overall survival. This trial aims to assess both the effectiveness and safety of the treatment.

Cholangiocarcinoma and Gallbladder Carcinoma>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Graft-versus-Host Disease: MC0518 Treatment Study

We are testing a new treatment, MC0518, for adults and adolescents with steroid-refractory acute graft-versus-host disease after stem cell transplantation. The study aims to see if it works better than the best available therapy and how it affects patients' quality of life.

Steroid Refractory Acute Graft Versus Host DiseaseConfirmation phase (III)6-10 visitsNo PlaceboInvestigational MedicinesHematologyOncology

Lung Cancer Treatment: Telisotuzumab Vedotin vs. Docetaxel

We are studying a new intravenous treatment for adults with previously treated non-squamous non-small cell lung cancer. The trial aims to see if it improves survival and quality of life compared to standard therapy.

Non-Squamous Non-Small Cell Lung CancerConfirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Tumor Treatment: Botensilimab and Balstilimab Study

We are studying a new combination of immune therapies for patients with specific tumor types to see if it can reduce tumor size before surgery. This trial aims to improve treatment effectiveness and safety.

dMMR Tumors≤3 monthsEfficacy phase (II)No PlaceboInvestigational MedicinesInternal MedicineOncology

Hereditary Angioedema: PHA-022121 Treatment Study

We are testing the safety of a new oral medication for treating acute angioedema attacks in patients with hereditary angioedema. The study will also evaluate how well it relieves symptoms during these attacks.

Hereditary AngioedemaEfficacy phase (II)Confirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteAllergologyInternal Medicine

Lung Cancer Treatment: Livmoniplimab and Budigalimab

We are studying a new combination of drugs for adults with untreated metastatic non-squamous non-small cell lung cancer. The goal is to see if this combination works better than a standard treatment with pembrolizumab and chemotherapy.

Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer>2 yearsEfficacy phase (II)Confirmation phase (III)>20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Immune Thrombocytopenia: New Combination Therapy

We are studying a new treatment combining four medications for patients with immune thrombocytopenia. The trial will evaluate its effectiveness, safety, and impact on quality of life.

Immune ThrombocytopeniaEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesHematologyInfectious Diseases

B-cell Non-Hodgkin Lymphoma: Surovatamig Treatment Study

We are studying how well surovatamig works and its safety for adults with certain types of blood cancers. This trial aims to learn more about its effects on lymphoma and patient experiences.

Relapsed or Refractory Non-Hodgkin Lymphoma>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteHematologyOncology

Cardiovascular Disease: New Care Strategies for Type 1 Diabetes

We are testing a new care approach to reduce cardiovascular disease risk in people with type 1 diabetes. This study also evaluates the safety of a medication called finerenone in this high-risk group.

Type 1 Diabetes>2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesPartially RemoteCardiologyEndocrinologyInternal Medicine

Baricitinib for Uveitis in Children with Juvenile Idiopathic Arthritis

We are studying whether the oral medication baricitinib is safe and effective for children aged 2 to under 18 with active uveitis linked to juvenile idiopathic arthritis. This research aims to improve treatment options for these young patients.

UveitisConfirmation phase (III)No PlaceboStandard MedicinesCost ReimbursementOphthalmologyRheumatology

Hidradenitis Suppurativa: New Antibiotic Treatment Study

We are evaluating a new antibiotic regimen for people with Hurley stage 2 Hidradenitis Suppurativa to see if it works better than standard treatment. The study will also look at pain relief and quality of life improvements.

Hidradenitis Suppurativa1-2 yearsConfirmation phase (III)6-10 visitsInvestigational MedicinesDermatologyInfectious Diseases

Lupus Nephritis: Obinutuzumab for Adolescents

We are studying the effects of obinutuzumab in adolescents with active lupus nephritis to see if it is more effective than a placebo. The trial also includes younger children to evaluate safety and how the drug works in them.

Lupus Nephritis>2 yearsEfficacy phase (II)Post-Trial Drug AccessStandard MedicinesPartially RemoteNephrologyPediatricsRheumatology

Epcoritamab for Relapsed Primary CNS Lymphoma

We are studying the effects of epcoritamab in patients with relapsed primary diffuse large B-cell lymphoma of the CNS who have been treated with lenalidomide and rituximab. The trial aims to evaluate its effectiveness, safety, and impact on quality of life.

Relapsed and Refractory Primary Diffuse Large B-Cell Lymphoma of the CNS>2 yearsEfficacy phase (II)Confirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesHematologyNeurologyOncology

Asthma Management: BIRDIE Trial

We are exploring if we can safely extend the dosing schedule of two asthma medications for patients with severe eosinophilic and T2-high asthma. This study looks at whether this approach maintains asthma control.

Severe AsthmaConfirmation phase (III)No PlaceboStandard MedicinesAllergologyPulmonology